Publication related to RSI or an RSI staff member

Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps.

Chemicals with estrogenic activity are derived from many different natural and synthetic processes and products, including endogenous production (e.g., estradiol, conjugated estrogens), drugs (e.g., ethinyl estradiol, conjugated estrogens), plants used as foods (phytoestrogens such as genistein, daidzein, S-equol), and man-made chemicals (xenoestrogens such as bisphenol A). Human exposure to low doses of endogenous estrogens, estrogenic drugs, phytoestrogens, and xenoestrogens has the potential to improve health or disrupt normal endocrine activity, as well as impact the diverse systems with which estrogens interact, including the cardiovascular system, and lipid and carbohydrate metabolism. Mechanisms of action and diversity of adverse and non-adverse effects following human exposure to low doses of estrogen active chemicals (EACs, defined as chemicals which interact with an estrogen receptor [ER]) are poorly understood. This review summarizes our current understanding of the pharmacological action with a focus on pharmacokinetics (PK) and toxicokinetics (TK) of several representative EACs in both physiological and pathological processes. The goal of this review is to assess the current state-of-the-science on: (i) the potential for EACs to interfere with endocrine activity, (ii) factors which contribute to endocrine-related clinical outcomes, and (iii) existing knowledge gaps. While classical PK approaches (compartmental or non-compartmental) can be used to characterize absorption, distribution, metabolism, and elimination of EACs, many of the detailed pharmacological characteristics necessary to understand benefit-risk balance have not yet been clarified. Pharmacological complexities mirror the complexity of determining whether and under what conditions exposure to estrogens in drugs, foods or to xenoestrogenic chemicals are beneficial or harmful to human health.

Authors

  • Mattison, Donald R, Mattison DR, Risk Sciences International , Ottawa, ON , Canada.

  • Karyakina, Nataliya, Karyakina N,

  • Goodman, Michael, Goodman M,

  • LaKind, Judy S, LaKind JS,

YEAR OF PUBLICATION: 2014
SOURCE: Crit Rev Toxicol. 2014 Sep;44(8):696-724. doi: 10.3109/10408444.2014.930813. Epub 2014 Aug 6.
JOURNAL TITLE ABBREVIATION: Crit Rev Toxicol
JOURNAL TITLE: Critical reviews in toxicology
ISSN: 1547-6898 (Electronic) 1040-8444 (Linking)
VOLUME: 44
ISSUE: 8
PAGES: 696-724
PLACE OF PUBLICATION: England
ABSTRACT:
Chemicals with estrogenic activity are derived from many different natural and synthetic processes and products, including endogenous production (e.g., estradiol, conjugated estrogens), drugs (e.g., ethinyl estradiol, conjugated estrogens), plants used as foods (phytoestrogens such as genistein, daidzein, S-equol), and man-made chemicals (xenoestrogens such as bisphenol A). Human exposure to low doses of endogenous estrogens, estrogenic drugs, phytoestrogens, and xenoestrogens has the potential to improve health or disrupt normal endocrine activity, as well as impact the diverse systems with which estrogens interact, including the cardiovascular system, and lipid and carbohydrate metabolism. Mechanisms of action and diversity of adverse and non-adverse effects following human exposure to low doses of estrogen active chemicals (EACs, defined as chemicals which interact with an estrogen receptor [ER]) are poorly understood. This review summarizes our current understanding of the pharmacological action with a focus on pharmacokinetics (PK) and toxicokinetics (TK) of several representative EACs in both physiological and pathological processes. The goal of this review is to assess the current state-of-the-science on: (i) the potential for EACs to interfere with endocrine activity, (ii) factors which contribute to endocrine-related clinical outcomes, and (iii) existing knowledge gaps. While classical PK approaches (compartmental or non-compartmental) can be used to characterize absorption, distribution, metabolism, and elimination of EACs, many of the detailed pharmacological characteristics necessary to understand benefit-risk balance have not yet been clarified. Pharmacological complexities mirror the complexity of determining whether and under what conditions exposure to estrogens in drugs, foods or to xenoestrogenic chemicals are beneficial or harmful to human health.
LANGUAGE: eng
DATE OF PUBLICATION: 2014 Sep
DATE OF ELECTRONIC PUBLICATION: 20140806
DATE COMPLETED: 20150511
DATE REVISED: 20140829
MESH DATE: 2015/05/12 06:00
EDAT: 2014/08/08 06:00
STATUS: MEDLINE
PUBLICATION STATUS: ppublish
LOCATION IDENTIFIER: 10.3109/10408444.2014.930813 [doi]
OWNER: NLM

Related RSI Experts

Donald Mattison

Chief Medical Officer, Senior Vice-President

Dr. Donald Mattison joined Risk Sciences International (RSI) in 2012 as Senior Vice-President and Chief Medical Officer, bringing with him a distinguished career spanning public health, clinical medicine, toxicology, and academic leadership. His appointment significantly strengthened RSI’s capacity to deliver...
Read More about Donald Mattison

Nataliya Karyakina

Senior Toxicologist, Health Risk Analyst

Dr. Nataliya Karyakina is a Senior Toxicologist and Health Risk Analyst at Risk Sciences International (RSI), where she has served since 2008. She plays a central role in RSI’s work at the intersection of chemical safety, regulatory science, and human...
Read More about Nataliya Karyakina